Vitamin Shoppe acquisition positive, says Sterne Agee After Vitamin Shoppe (VSI) agreed to buy vitamins/supplements manufacturer FDC Vitamins, Sterne Agee believes that Vitamin Shoppe will obtain several strategic benefits from the deal. The firm predicts that the deal will be slightly accretive in the near-term and generate greater benefits in in the next two to three years are synergies are reaped. The firm keeps a Buy rating on Vitamin Shoppe.
News For VSI From The Last 14 Days
Check below for free stories on VSI the last two weeks.
Vitamin Shoppe comps should should show acceleration, says RW Baird Baird expects Q2 earnings at Vitamin Shoppe to be in-line but believes its comparable sales should show an acceleration and an improved margin performance relative to prior quarters. The firm also believes concerns over increased promotional activity are overblown. Baird likes the stock at current levels and keeps a Buy rating with a $55 price target on the shares.
Vitamin Shoppe recommended ahead of Q2 report at Goldman Goldman believes Vitamin Shoppe (VSI) competitive pressures are overblown and that the company has relatively low overlap with GNC (GNC) and that recent price cuts have had minimal impact. The firm expects Vitamin Shoppe's Q2 to mark the beginning of sharp earnings acceleration and better execution and recommends buying shares ahead of the Q2 report. Shares are rated Conviction Buy with a $60 price target.